Univariate analysis | HRs | 95% CI | p -value |
---|---|---|---|
Gender (male vs. female) | 0.583 | 0.280-1.211 | 0.148 |
Age (≤40, > 40 & ≤60, > 60) | 0.649 | 0.359-1.175 | 0.154 |
T-stage (T1, T2, T3 ,T4) | 1.428 | 0.902-2.261 | 0.129 |
Node metastasis (N0, N1) | 1.960 | 0.810-4.745 | 0.136 |
Distant metastasis (M0, M1) | 3.558 | 1.695-7.469 | 0.001 |
Unresectability (resectable vs. unresectable) | 2.917 | 1.025-8.298 | 0.045 |
Tumor Size (≤2 cm, > 2 cm & ≤ 5 cm, > 5 cm) | 2.419 | 1.191-4.917 | 0.015 |
Histological differentiation (Well, Moderate, Poor; n) | 1.154 | 0.777-1.714 | 0.478 |
Karnofsky performance status scale (continuous variable)* | 0.962 | 0.936-0.988 | 0.005 |
High-serum CA19-9 (≤40 U/ml vs. > 40 U/ml) | 1.811 | 0.788-4.160 | 0.162 |
High-serum CEA (≤3 ng/ml vs. > 3 ng/ml) | 2.137 | 1.062-4.298 | 0.033 |
High-serum sCD40L (≤35,000 ng/ml vs. > 35,000 ng/ml) | 2.468 | 1.162-5.242 | 0.019 |
Multivariate analysis | HRs † | 95% CI | p -value |
Distant metastasis (M0, M1) | 3.469 | 1.375-8.749 | 0.008 |
Unresectability (resectable vs. unresectable) | 0.588 | 0.168-2.060 | 0.406 |
Tumor Size (≤2 cm, > 2 cm & ≤ 5 cm, > 5 cm) | 2.454 | 1.075-5.602 | 0.033 |
Karnofsky performance status scale (continuous variable)* | 0.969 | 0.940-0.998 | 0.038 |
High-serum CEA (≤3 ng/ml vs. > 3 ng/ml) | 1.354 | 0.549-3.340 | 0.511 |
High-serum sCD40L (≤35,000 ng/ml vs. > 35,000 ng/ml) | 2.509 | 1.038-6.067 | 0.041 |